We are testing our investigational enzyme replacement therapy (ERT), INZ-701, to see whether it can help people with rare diseases linked to the PPi-Adenosine Pathway.
Dev
ENPP1 Deficiency
Our lead candidate, INZ-701, is in clinical development for the potential treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis – all driven by disruptions in the PPi-Adenosine Pathway. Currently, there are no therapeutic options for these three rare disorders. We are pioneering the development of effective therapies for these patients and their families.
Learn more about our clinical studies.
| Indication | Stage of Development | ||||
| Research | IND-Enabling | Phase 1 | Phase 2 | Phase 3 | |
|---|---|---|---|---|---|
| ENPP1 Deficiency | INZ-701 | ||||
) | | | | | |
| ABCC6 Deficiency | INZ-701 | ||||
| | | | | |
| Calciphylaxis | INZ-701 | ||||
| | | | | |
| OPLL – Ossification of the Posterior Longitudinal Ligament | Next Gen ERT | ||||
| | | | | |
| Diseases of PPi-Adenosine Pathway | Gene Therapy | ||||
| | | | | |
| Research | IND-Enabling | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
| ENPP1 Deficiency | INZ-701 | ||||
| ABCC6 Deficiency | INZ-701 | ||||
| Calciphylaxis | INZ-701 | ||||
| OPLL – Ossification of the Posterior Longitudinal Ligament | Next Gen ERT | ||||
| Diseases of PPi-Adenosine Pathway | Gene Therapy | ||||
We are enrolling patients in clinical trials for a potential new treatment. With your participation, we can better understand these diseases and help inform possible future treatment options.
